Ghebeh, Hazem
Al-Sayed, Adher
Eiada, Riham
Cabangon, Leilani
Ajarim, Dahish
Suleman, Kausar
Tulbah, Asma
Al-Tweigeri, Taher
Funding for this research was provided by:
AstraZeneca (ESR 14-10649)
Article History
Received: 8 December 2020
Accepted: 1 September 2021
First Online: 27 September 2021
Competing interests
: Dr. Taher Al-Tweigeri has received speaking honoraria from Roche, Novartis, and Lilly. He also received travel support from Roche and Novartis and has served on advisory committees for Roche, Lilly, and Novartis. Dr. Hazem Ghebeh received travel support from AstraZeneca. Other authors declare no potential conflicts of interest.